3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Status
Recruiting
3
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
3
Sponsor
Cancer Type
Lymphoid
21
Dermatologic
9
Sarcoma
3
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Sarcoma
3
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Leiomyosarcoma
1
Hyperthermia
1
Interventions
Cyclophosphamide
54
Specimen Handling
50
Magnetic Resonance Spectroscopy
49
pembrolizumab
43
Doxorubicin
43
Radiotherapy
42
Temozolomide
37
Biopsy
34
Radiation
29
Nivolumab
28
fludarabine
23
Vincristine
22
Irinotecan
21
Gemcitabine
21
X-Rays
20
Surgical Procedures, Operative
19
Ifosfamide
19
atezolizumab
17
cabozantinib
15
Ipilimumab
15
olaparib
13
Sunitinib
13
Paclitaxel
13
regorafenib
12
fludarabine phosphate
12
Phantoms, Imaging
12
Imatinib Mesylate
12
Etoposide
12
Blood Specimen Collection
12
Carboplatin
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Dacarbazine
×
Sarcoma
×
1 year
×
Clear all
NCT03016819
2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3
Recruiting
325 enrolled
NCT06835049
2025-12-30
TNT-HYPE
Swiss Cancer Institute
Phase 2
Recruiting
24 enrolled
NCT03805022
2025-10-02
CIRSARC
Institut Bergonié
Phase 3
Recruiting
351 enrolled